DMAC logo

DIAMEDICA THERAPEUTICS INC

DMACNASDAQ
🏆 #2909 by market capEarnings Nov 18 · PostUS Equity
——
Quote unavailable
🔔
Track DMAC
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$469M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
44
Weak
No chart data available for DMAC.

Trading Snapshot

Day Range
—
52-Week Range
$5.25 – $10.42
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
53.9M
Next Earnings
2026-11-18

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-12.1
P/S Ratio
0.0x
EPS (TTM)
$-0.70
Dividend Yield
0.00%
Dilution (1yr)
+9.7%
DMAC logo

DIAMEDICA THERAPEUTICS INC

DMAC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$34M▲ +28.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$29M▲ +31.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
47.0M▲ +9.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$15M▲ +$13M YoY
StockOtter · stockotter.space

About DIAMEDICA THERAPEUTICS INC

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100
Analyst data unavailable.

Latest News & Updates

News unavailable.